Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-10-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
董事、监事、高管持股变动管理制度（2023年10月）
Governance Information Classification · 95% confidence The document is titled "董事、监事、高管持股变动管理制度" which translates to "Management System for Shareholding Changes of Directors, Supervisors, and Senior Executives". It details the rules, procedures, and regulatory compliance requirements for shareholding disclosures and restrictions for company directors and senior management. It references relevant laws and stock exchange regulations, and outlines reporting and locking mechanisms for shares held by insiders. This is a governance-related document focusing on internal rules and management of shareholding changes by key personnel, rather than an announcement of a specific transaction or a report of a single share transaction. It is not a report of a specific share transaction (DIRS), nor a general regulatory filing (RNS) because it is a formal internal policy document. It fits best under Governance Information (CGR) as it details the company's internal governance practices regarding insider shareholding management.
2023-10-25 Chinese
独立董事专门会议制度（2023年10月）
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议制度' which translates to 'Independent Directors Special Meeting System' and outlines the governance rules and procedures for independent directors' meetings at the company 福安药业（集团）股份有限公司. It references relevant laws, regulations, and company bylaws related to corporate governance and independent directors' duties. The content is focused on governance structure, meeting procedures, and directors' responsibilities rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial data, earnings information, or regulatory filings related to financial performance. This document fits the description of a Governance Information report detailing internal rules and board structure. The document length is 1921 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Therefore, the appropriate classification is Governance Information (CGR).
2023-10-25 Chinese
独立董事关于第五届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific matters discussed at the company's 13th board meeting of the 5th session. It includes opinions on providing guarantees for subsidiary financing and changes in accounting estimates. The document references compliance with laws and company articles but does not contain full financial statements or comprehensive financial data. It is a formal opinion related to board/management decisions rather than a full audit report or annual/interim report. The document length is short (831 characters), and it is not an announcement of a report publication but an official opinion document. Therefore, it fits best under Board/Management Information (MANG).
2023-10-25 Chinese
关于公司控股股东、董事、高级管理人员自愿承诺不减持的公告
Director's Dealing Classification · 95% confidence The document is an announcement from a company about a voluntary commitment by its controlling shareholders, directors, and senior management not to reduce their shareholdings for a specified period. It includes details about the commitment, the parties involved, and the company's supervisory measures. There is no financial data, no report attached or referenced as being published, and no mention of regulatory certifications or filings. The content focuses on insider shareholding behavior and commitments, which aligns with the category of Director's Dealing (DIRS), as it relates to personal share transactions or commitments by company directors and executives.
2023-09-21 Chinese
关于举行2023年半年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding a 2023 half-year online earnings explanation meeting (业绩说明会). It references the 2023 half-year report having been published on August 30, 2023, but does not contain the report itself or detailed financial data. The document invites investors to participate in the online meeting and submit questions. The length is short (813 characters), and the content is clearly an announcement of an event related to the interim report, not the report itself. Therefore, it fits best as an Investor Presentation (IP) since it is about a detailed presentation for investors focusing on financials and business updates, rather than the report or a simple announcement of report publication (RPA).
2023-09-20 Chinese
关于子公司收到药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding its subsidiary receiving an approval notice from the National Medical Products Administration for a drug supplement application. It details the drug name, registration classification, approval numbers, and implications for market competitiveness. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The document is an official regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Earnings Release, or Capital Update.
2023-09-18 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.